Genenta Science S.p.A. Stock (NASDAQ:GNTA)
Previous Close
$3.83
52W Range
$2.20 - $7.28
50D Avg
$3.88
200D Avg
$4.34
Market Cap
$70.94M
Avg Vol (3M)
$20.39K
Beta
0.65
Div Yield
-
GNTA Company Profile
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
GNTA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| MLYS | Mineralys Therapeutics, Inc. |
| PHVS | Pharvaris N.V. |
| CSBR | Champions Oncology, Inc. |
| MOLN | Molecular Partners AG |
| MNOV | MediciNova, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| ADAG | Adagene Inc. |
| PMVP | PMV Pharmaceuticals, Inc. |
| OPT | Opthea Limited |
| RZLT | Rezolute, Inc. |
| AVTE | Aerovate Therapeutics, Inc. |
| JANX | Janux Therapeutics, Inc. |
| ANTX | AN2 Therapeutics, Inc. |
| PEPG | PepGen Inc. |